PharmaNutra SpAMIL:PHN -1.91%85 PB Ratio is 11.19 as of Jun. 26, 2026, which is 16% above its 10-year median of 9.64. GuruFocus rates MIL:PHN with a GF Score™ of 85/100 and a GF Value™ of €71.41 (Modestly Overvalued). The stock has 6 warning signs investors should review. Among 922 Drug Manufacturers companies, PharmaNutra SpA ranks worse than 93.71% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-06-26), PharmaNutra SpA's share price is €87.20. PharmaNutra SpA's Book Value per Share for the quarter that ended in Mar. 2026 was €7.79. Hence, PharmaNutra SpA's PB Ratio of today is 11.19.
Warning Sign:
PharmaNutra SpA stock PB Ratio (=11.55) is close to 3-year high of 11.98.
The historical rank and industry rank for PharmaNutra SpA's PB Ratio or its related term are showing as below:
MIL:PHN'
s PB Ratio Range Over the Past 10 Years
Min: 5.8 Med: 9.64 Max: 17.92
Current: 11.83
During the past 11 years, PharmaNutra SpA's highest PB Ratio was 17.92. The lowest was 5.80. And the median was 9.64.
MIL:PHN's PB Ratio is ranked worse than 93.71% of 922
companies
in the Drug Manufacturers industry
Industry Median: 1.825
vs MIL:PHN: 11.83
During the past 12 months, PharmaNutra SpA's average Book Value Per Share Growth Rate was 16.10% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was 12.10% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 13.10% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 26.00% per year.
During the past 11 years, the highest 3-Year average Book Value Per Share Growth Rate of PharmaNutra SpA was 62.40% per year. The lowest was 11.60% per year. And the median was 22.30% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
PharmaNutra SpA PB Ratio Related Terms
PharmaNutra SpA PB Ratio Historical Data
* Premium members only.
The historical data trend for PharmaNutra SpA's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, PharmaNutra SpA's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PharmaNutra SpA PB Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, PharmaNutra SpA's PB Ratio distribution charts can be found below:
* The bar in red indicates where PharmaNutra SpA's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
PharmaNutra SpA's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
PharmaNutra SpA (MIL:PHN) has a PB Ratio of 11.19 as of Jun. 26, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PharmaNutra SpA and its competitors. This is 16% above median its historical median of 9.64. Over the past decade, PharmaNutra SpA's PB Ratio has ranged from 5.80 to 17.92. According to the industry distribution chart, PharmaNutra SpA ranks #864 out of 922 companies in the Drug Manufacturers industry, placing it in the top 93.7%.
Is PharmaNutra SpA's PB Ratio too high?
PharmaNutra SpA's current PB Ratio of 11.19 is 16% above median its 10-year median of 9.64. Over the past 10 years, this metric has ranged from a low of 5.80 to a high of 17.92. The Drug Manufacturers industry median PB Ratio is 1.83. PharmaNutra SpA's value of 11.19 is 513.2% above this industry median. Based on the distribution chart, PharmaNutra SpA ranks #864 out of 922 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, PharmaNutra SpA has a GF Score™ of 85/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does PharmaNutra SpA's PB Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, PharmaNutra SpA ranks #864 out of 922 companies for PB Ratio. This places PharmaNutra SpA in the lower half of its industry. The industry median PB Ratio is 1.83. PharmaNutra SpA's value of 11.19 is 513.2% above this benchmark. Historically, PharmaNutra SpA's own PB Ratio has ranged from 5.80 to 17.92 over the past decade. While the company's 10-year median is 9.64 vs. the industry median of 1.83, PharmaNutra SpA has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Drug Manufacturers company?
The median PB Ratio among Drug Manufacturers companies is 1.83, based on 922 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. PharmaNutra SpA's current PB Ratio of 11.19 is 513.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on PharmaNutra SpA and its competitors. For the Drug Manufacturers industry, the median PB Ratio is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. PharmaNutra SpA's current PB Ratio is 11.19, which is 16% above median its own 10-year median of 9.64. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PharmaNutra SpA stock overvalued right now?
Based on GuruFocus' analysis, PharmaNutra SpA (MIL:PHN) is currently considered Modestly Overvalued. The stock's GF Value™ is €71.41, compared to a current price of €87.20 — trading 22.1% above its estimated fair value. The current PB Ratio is 11.19, which is 16% above median its 10-year median of 9.64 and 513.2% above the Drug Manufacturers industry median of 1.83. PharmaNutra SpA's overall GF Score™ is 85/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For PharmaNutra SpA (MIL:PHN), the current PB Ratio is 11.19 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PharmaNutra SpA (MIL:PHN) Overvalued in 2026?
Based on GuruFocus' analysis, PharmaNutra SpA stock appears to be overvalued.
The current stock price of €87.20 is trading 22.1% above its estimated GF Value™ of €71.41.
GuruFocus considers PharmaNutra SpA to be Modestly Overvalued.
Key valuation signals for MIL:PHN:
PB Ratio: 11.19 (16% above median its 10-year median of 9.64)
GF Value™: €71.41 vs. price of €87.20 (22.1% above fair value)
Industry Position: 513.2% above the Drug Manufacturers median (#864 of 922)
No single metric tells the full story. See the MIL:PHN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PharmaNutra SpA is a pharmaceutical company. The company is engaged in the research, design, development, and marketing of nutraceutical supplements and medical devices. The products of the company include SiderAL Folic, UltraMag, Cetilar, and others. The company operates in Europe, the Middle East, South America, the Far East, and other regions.
85GF Score
Get the complete analysis for MIL:PHN
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:PHN has been successfully added to your 
